- Immuron Limited (ASX: IMC; NASDAQ: IMRN) officially launched **PROIBS®** for Irritable Bowel Syndrome (IBS) into the **Australian market** on **October 24, 2025**.  **[1660046_0001213900-25-101838_ea026238501ex99-1_immuron.htm:0]** 
- PROIBS® is a certified medical device for treating IBS symptoms, and Immuron has already received pharmacy orders for the product.  **[1660046_0001213900-25-101838_ea026238501ex99-1_immuron.htm:0]** 
- The launch strategy focuses on online and selected pharmacies, supported by digital marketing and social media, timed for the peak festive season when IBS symptom triggers are highest.  **[1660046_0001213900-25-101838_ea026238501ex99-1_immuron.htm:0]** 
- The Australian "Digestives & Intestinal Remedies" market, which includes IBS treatments, is estimated to generate **AU$221.14 million in 2025** with a projected annual growth rate of **3.28%**.  **[1660046_0001213900-25-101838_ea026238501ex99-1_immuron.htm:0]**

Immuron Launches PROIBS for Irritable Bowel Syndrome in Australia

- Immuron Limited's CEO, Steven Lydeamore, presented at the AusBiotech Invest 2025 conference on **October 21, 2025**, highlighting the company's financial performance and strategic pipeline.  **[1660046_0001213900-25-100505_ea026189801ex99-1_immuron.htm:0]** **[1660046_0001213900-25-100505_ea0261898-6k_immuron.htm:0]** 
- The company reported **Global Sales Revenue of AUD$7.3 million** for **FY2025**, marking a **49% increase** over the prior year, with **Q1 FY2026 Global Sales Revenue** for Travelan® reaching **AUD$2.0 million**, up **34%** from Q1 FY2025.  **[1660046_0001213900-25-100505_ea026189801ex99-1_immuron.htm:3]** 
- Immuron's product pipeline includes **Travelan® (IMM-124E)**, projected to achieve peak U.S. sales of **US$102 million** with anticipated FDA approval in **2027-2028**, and **IMM-529** for Clostridioides difficile infection, with projected peak U.S. sales of **~US$400 million** and potential FDA approval in **2028**.  **[1660046_0001213900-25-100505_ea026189801ex99-1_immuron.htm:4]** 
- Immuron also has an exclusive distribution agreement for **ProIBS®** in Australia and New Zealand, addressing an Australian IBS treatment market estimated at **AU$221.14 million in 2025**.  **[1660046_0001213900-25-100505_ea026189801ex99-1_immuron.htm:1]** **[1660046_0001213900-25-100505_ea026189801ex99-1_immuron.htm:2]**

Immuron CEO Presents FY25 Financials and Strategic Pipeline at AusBiotech Invest 2025

- Immuron Limited announced a proposed **placement** of **1,133,840** Ordinary Fully Paid shares (ASX code: IMC).  **[1660046_0001213900-25-099709_ea026158201ex99-1_immuron.htm:0]** 
- The shares are proposed to be issued on **October 17, 2025**, for a **cash consideration** of **AUD 0.08860** per security.  **[1660046_0001213900-25-099709_ea026158201ex99-1_immuron.htm:0]** 
- The purpose of this issue is to fund **research and development activities** and provide **ongoing working capital**.  **[1660046_0001213900-25-099709_ea026158201ex99-1_immuron.htm:1]** 
- These shares were purchased by **US investors** through the company's US At-The-Market (ATM) facility.  **[1660046_0001213900-25-099709_ea026158201ex99-1_immuron.htm:1]**

Immuron Limited Announces Proposed Placement of Shares

- Immuron Limited announced **unaudited Q1 FY26 global sales** of **AUD$2.0 million**, representing a **34% increase** compared to the prior comparative period.  **[1660046_0001213900-25-098382_ea026102601ex99-1_immuron.htm:0]**  This information was published on **October 14, 2025**.  **[1660046_0001213900-25-098382_ea0261026-6k_immuron.htm:0]** 
- **Australian Q1 sales** grew by **52%** to **AUD$1.6 million**, driven by increased awareness, same-store growth, new store listings, and increased South East Asian travel.  **[1660046_0001213900-25-098382_ea026102601ex99-1_immuron.htm:0]** 
- **U.S. Q1 sales** increased by **44%** to **AUD$0.4 million**, attributed to marketing initiatives including an improved Amazon.com store and increased social media marketing.  **[1660046_0001213900-25-098382_ea026102601ex99-1_immuron.htm:0]** 
- **Canadian Q1 sales** were **AUD$0.0 million**, a **92% decrease** on the prior comparative period, as Q1 is typically the lowest travel period, with sales expected to pick up later in the calendar year.  **[1660046_0001213900-25-098382_ea026102601ex99-1_immuron.htm:0]**

Immuron Reports Q1 FY26 Sales Growth

- Immuron Limited will hold its **2025 Annual General Meeting** on **Tuesday, 11 November 2025, at 11.15 am AEDT** to consider several resolutions.  **[1660046_0001213900-25-097934_ea026089401ex99-1_immuron.htm:0]** 
- Shareholders will vote on the re-election of **Prof Ravi Savarirayan** and **Mr Paul Brennan** as Non-Executive Directors.  **[1660046_0001213900-25-097934_ea026089401ex99-1_immuron.htm:0]** 
- The company is seeking approval for an increase in its equity securities placement capacity by **10%** under ASX Listing Rule 7.1A and ratification of prior issues totaling **16,095,046 shares** under Listing Rule 7.1 and **22,799,834 shares** under Listing Rule 7.1A.  **[1660046_0001213900-25-097934_ea026089401ex99-1_immuron.htm:1]** **[1660046_0001213900-25-097934_ea026089401ex99-1_immuron.htm:14]** 
- Resolutions also include the approval to issue **1,000,000 options each** to four directors (Dr Jeannette Joughin, Mr Daniel Pollock, Prof Ravi Savarirayan, and Mr Paul Brennan) with an exercise price of **$0.11** and an expiry date of 4 years from the grant date of 3 October 2025.  **[1660046_0001213900-25-097934_ea026089401ex99-1_immuron.htm:1]** **[1660046_0001213900-25-097934_ea026089401ex99-1_immuron.htm:11]** **[1660046_0001213900-25-097934_ea026089401ex99-1_immuron.htm:12]**

Immuron Ltd to hold 2025 Annual General Meeting, seeking approvals for director re-elections, equity issuance, and executive options

- Immuron Limited has submitted an **Investigational New Drug (IND) application** to the FDA for **IMM-529**, which is proposed for the treatment of *Clostridioides difficile* infection (CDI) and prevention of recurrent CDI (rCDI).  **[1660046_f4e21e36157543ed8584082d726ddaab_0]** **[1660046_f4e21e36157543ed8584082d726ddaab_1]** 
- The company plans to **initiate a Phase 2 clinical trial** for IMM-529 in individuals with CDI during the **first half of 2026**.  **[1660046_f4e21e36157543ed8584082d726ddaab_1]** 
- Independent market analysis by Lumanity suggests a base case **annual revenue potential of approximately US$400M** for IMM-529, contingent on demonstrated efficacy.  **[1660046_f4e21e36157543ed8584082d726ddaab_1]** 
- IMM-529 is designed as an adjunctive therapy with a novel **3-target approach** against *C. diff* virulence components, showing promising results in pre-clinical models for preventing primary disease, protecting against recurrence, and treating primary disease.  **[1660046_f4e21e36157543ed8584082d726ddaab_2]**

Immuron Submits IMM-529 IND to FDA

- Immuron Limited has submitted an Investigational New Drug (IND) application to the FDA for **IMM-529**, intended for the treatment of *Clostridioides difficile* infection (CDI) and prevention of recurrent CDI (rCDI).  **[1660046_0001213900-25-097170_ea026064701ex99-1_immuron.htm:0]** 
- The company plans to **initiate a Phase 2 clinical trial** for IMM-529 in the **first half of 2026**.  **[1660046_0001213900-25-097170_ea026064701ex99-1_immuron.htm:0]** 
- Independent market analysis by Lumanity projects the base case annual revenue potential for IMM-529 at approximately **US$400 million**.  **[1660046_0001213900-25-097170_ea026064701ex99-1_immuron.htm:0]** 
- Pre-clinical results showed IMM-529's potential in preventing primary disease (**80%**), protecting against disease recurrence (**67%**), and treating primary disease (**78.6%**).  **[1660046_0001213900-25-097170_ea026064701ex99-1_immuron.htm:1]**

Immuron Submits IMM-529 IND to FDA for *C. diff* Treatment

- Immuron Limited has increased the amount available for sale under its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.  **[1660046_0001213900-25-095881_ea0260180-6k_immuron.htm:1]** 
- The company may now offer and sell an **additional aggregate offering price of up to $2,847,954** in American Depositary Shares (ADSs).  **[1660046_0001213900-25-095881_ea0260180-6k_immuron.htm:1]** **[1660046_0001213900-25-095881_ea026018001ex5-1_immuron.htm:1]** 
- This increase is effective as of **October 3, 2025**, and is separate from the **$2,068,866 of securities already sold** under the program in the 12-calendar month period ending on that date.  **[1660046_0001213900-25-095881_ea0260180-6k_immuron.htm:1]** 
- Each ADS is convertible into **40 fully paid ordinary shares**.  **[1660046_0001213900-25-095881_ea026018001ex5-1_immuron.htm:1]**

Immuron Increases At-The-Market Offering Capacity

- Immuron Limited reported **FY25 Global Sales Revenue of A$7.3 million**, marking a **49% increase** year-over-year, driven by **North American Travelan® sales which grew 76% to A$2.0 million**.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]** **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:4]** 
- As of June 30, 2025, the company held **A$5.9 million in cash and term deposits**, with an additional A$2.8 million raised in July 2025.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]** **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:4]** 
- Key upcoming clinical milestones include the anticipated release of **topline data for the Travelan® (IMM-124E) Uniformed Services University trial in October 2025** and the **submission of an FDA IND for IMM-529 by September 30, 2025**, with approval expected by **December 31, 2025**.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]** **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:5]**  
- The Australian launch of **ProIBS® is planned for Q1 CY2026**.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]**

Immuron Ltd. Reports Strong FY25 Sales Growth and Outlines Key Clinical Milestones

- Immuron Limited reported a **48.6% increase** in revenue from ordinary activities, reaching **$7,287,002** for the year ended June 30, 2025, primarily driven by Travelan® sales in Australia and North America.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:0]** **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:1]** 
- The company's loss after tax decreased by **24.3%** to **($5,253,209)** for the year ended June 30, 2025, compared to ($6,936,957) in the prior year.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:0]** **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:1]** 
- Cash and cash equivalents significantly declined to **$2,830,526** as of June 30, 2025, down from $11,657,315 at June 30, 2024.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:0]** **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:1]** 
- Post-reporting period, in July 2025, Immuron Limited raised gross proceeds of **USD$1,822,322 (AUD$2,809,177)** through an At The Market Facility.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:7]**

Immuron (IMRN)